Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...
Donald Trump's war against Iran is part of a terrifying new era of American imperialism, one in which the military budget ...
The automotive EBIT margin came in at 5.3%. Excluding the EUR 1.3 billion depreciation resulting from the PPA of BMW Brilliance Automotive, the EBIT margin reached 6.4% for the year. And that still ...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...
GPGI, Inc. (NYSE:GPGI) Q4 2025 Earnings Call Transcript March 12, 2026 GPGI, Inc. misses on earnings expectations. Reported EPS is $0.23 EPS, expectations were $0.2336. Operator: Good day, and thank ...
Q4 2025 Earnings Call March 4, 2026 8:30 AM ESTCompany ParticipantsJim Floros - Vice President of Investor RelationsMike Greenley ...
Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilize ...
At the invitation of His Excellency Narendra Modi, Prime Minister of India, the Right Honourable Mark Carney, Prime Minister of Canada, paid an official visit to India from February 27 -- March 2, ...
Hello, and welcome to today's conference call to discuss Rocket Lab USA, Inc.'s fourth quarter and full year 2025 financial ...
Modernizing biomanufacturing methods and reducing regulatory burdens are key landmarks on India’s roadmap for expanding ...
Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results